Enova International Issues $300.9M Securitization Notes (2026-A)

What Happened

• On August 21, 2026, a wholly‑owned indirect subsidiary of Enova, NetCredit Combined Receivables B, LLC (the “Issuer”), issued $300,886,000 aggregate principal of 2026-A notes in a securitization (the “ENVA 2026‑A Transaction”).
• The notes break down into Class A $240,709,000, Class B $44,341,000 and Class C $15,836,000. The Issuer pledged a pool of approximately $316.72 million of unsecured consumer installment loans as collateral. The notes were issued under an Indenture dated August 21, 2026, with Citibank, N.A. as Trustee; final maturity is September 20, 2032.
• The 2026‑A Notes are obligations of the Issuer only and are not guaranteed by Enova. Net proceeds will be used to acquire the receivables from Enova subsidiaries, fund a reserve account and pay transaction fees and expenses.

Key Details

• Total issued: $300,886,000 (Class A $240,709,000; Class B $44,341,000; Class C $15,836,000).
• Collateral: ~ $316.72 million of unsecured consumer installment loans (subject to eligibility criteria in the Indenture).
• Interest coupons (fixed): Class A 5.88% p.a.; Class B 7.68% p.a.; Class C 10.64% p.a.; maturity Sept 20, 2032.
• Distribution/registration: Notes not registered under the Securities Act; offered to qualified institutional buyers under Rule 144A and to persons outside the U.S. under Regulation S.

Why It Matters

• This transaction provides Enova’s business with liquidity by selling a pool of loans to a subsidiary issuer and funding the company’s operations or capital needs without the parent guaranteeing the notes.
• Because the notes are obligations of the subsidiary (not Enova) and include covenants and eligibility rules for the collateral, investors should note there is limited recourse to Enova itself; covenant breaches could lead to acceleration, sale of collateral, or termination of the facility.
• Fixed coupons and a long final maturity (2032) lock in funding costs for the securitization classes; the offering being limited to institutional and non‑U.S. buyers affects marketability and regulatory treatment.